ArticleCommunications biology2025
Single-cell transcriptomic profiling reveals cell type heterogeneity between HFpEF and HFrEF.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cardiac fibroblast diversity in HFpEF: states, niches, interorgan drivers and targets.Nature reviews. Cardiology · 2026Review
- Single-cell transcriptomics reveals how Shenfu Qiangxin pill ameliorates HFpEF by modulating cardiac cellular heterogeneity.Chinese medicine · 2026Article
- Transcriptome Reprogramming in Heart Failure: The Hidden Splicing Code.Current cardiology reports · 2026Review
- Addressing Unmet Needs in Heart Failure with Preserved Ejection Fraction: Multi-Omics Approaches to Therapeutic Discovery.International journal of molecular sciences · 2026Review
- Neutrophil Heterogeneity after Myocardial Infarction.Journal of innate immunity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) as a high heterogeneity clinical syndrome, is commonly associated with diastolic dysfunction, and has no effective therapy, which is obviously distinct from Heart failure with reduced ejection fraction (HFrEF). Currently the differences of cell type heterogeneity between HFpEF and HFrEF remain largely unknown. Here we illustrate an atlas consisting of 21,747 cardiac cells, including both HFpEF and HFrEF. Cell-cell communication analysis reveals cardiomyocytes rather than endothelium or fibroblasts were dominant communication "hub" in HFpEF. The subtypes of cardiomyocytes are highly heterogeneous between HFpEF and HFrEF. Notably, a specific subtype of cardiomyocytes shows significant gene expression associated with the metabolism of fatty acids. Additionally, regulon analysis reveals that Ppargc1a, Atf6, E2f6, and Mitf exhibited specific elevated regulation in the subtype of cardiomyocytes of HFpEF. Furthermore, we have identified 210 HF susceptibility genes from HF-associated GWAS data. After integrating scRNA-seq, GWAS, and eQTL data, the genetic susceptibility underlying HFpEF and HFrEF were discussed. In conclusion, this study not only comprehensively characterizes the differences of cardiomyocytes changes but also provides insights into potential targets for cell type- and subtype-specific molecules between HFpEF and HFrEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.